Ticker Report Research analysts at StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR - Get Free Report) in a research note issued on Friday. The brokerage set a "buy" rating on the...\n more…
Ticker Report StockNews.com began coverage on shares of Acorda Therapeutics (NASDAQ:ACOR - Free Report) in a research report released on Thursday morning. The firm issued a buy rating on the biopharmaceutical...\n more…
Seeking Alpha - Healthcare Acorda Therapeutics announces Nasdaq delisting notification...\n more…
Business Wire Acorda Therapeutics, Inc. (Nasdaq: ACOR) announced that Nasdaq Stock Market ('Nasdaq') today notified the Company that it will suspend trading in and delist the Company's common stock, effective with...\n more…